Molekulargenetische Untersuchung von Genen der Phase I- und Phase II-Enzyme bei Lungenemphysem
File | Description | Size | Format | |
---|---|---|---|---|
00011630.pdf | 1.93 MB | Adobe PDF | View/Open |
Other Titles: | Molecular genetic examination of genes of phase I- and phase II-enzymes of pulmonary emphysema | Authors: | Breuer, Renee | Supervisor: | Werner, Schloot | 1. Expert: | Schloot, Werner | Experts: | Beyersmann, Detmar | Abstract: | To examine the risk of chronic obstructive pulmonary disease (COPD) associated with genetic polymorphism of glutathione-S-transferase genes (GMTM1, GSTM3, GSTT1, GSTP1), epoxides hydrolases (mEH) and the cytochrome P450 genes (CYP1A1 and CYP2D6) were studied by different PCR-methods in 125 patients with COPD and 264 healthy individuals. Individual susceptibility to COPD is likely to be modified by genotype for enzymes involved in the detoxification of xenobiotics. A relationship between COPD and CYP1A1*1*2B, CYP2D6*1*1 and mEH*3*3 (OR 1,72, CI 95%: 0,76-3,91; OR 1,49, CI 95%: 0,97-2,29; OR 1,74, CI 95%: 0,93-6,59) were not significant but smoker with CYP2D6*1*1 display a 9,16-fold higher risk of developing COPD. Also the genotypes of GSTM1*0*0, GSTT1*1*1, GSTP1*A*A und GSTM3*A*A (OR 1,56, CI 95%: 1,02-2,4; OR 1,58, CI 95%: 1,00-2,45; OR 2,54, CI 95%: ; OR 2,55, CI 95%) were associated with a higher risk. Otherwise the genotypes CYP1A1*1*2A and mEH*1*1 (OR 0,65, CI 95%: 0,28-1,48; OR 0,44, CI 95%: 0,26-0,75) deliver a significant protection of COPD. |
Keywords: | COPD- glutathione-S-transferase; epoxides hydrolases; cytochrome P450 | Issue Date: | 17-Dec-2002 | Type: | Dissertation | Secondary publication: | no | URN: | urn:nbn:de:gbv:46-diss000116305 | Institution: | Universität Bremen | Faculty: | Fachbereich 02: Biologie/Chemie (FB 02) |
Appears in Collections: | Dissertationen |
Page view(s)
193
checked on Apr 2, 2025
Download(s)
39
checked on Apr 2, 2025
Google ScholarTM
Check
Items in Media are protected by copyright, with all rights reserved, unless otherwise indicated.